Anti-Mouse TIM-2 – Purified in vivo GOLD™ Functional Grade

Clone RMT2-14 is a rat monoclonal antibody targeting the T cell immunoglobulin and mucin domain-2 (TIM-2) molecule. It is commonly used in in vivo studies involving mice for several applications:

1. Flow Cytometry and Immunohistochemistry: RMT2-14 is utilized for identifying and analyzing TIM-2 expression in various cell types, including those in the spleen and other tissues, through methods like flow cytometry and immunohistochemistry.

2. Functional Assays: This antibody is used in functional assays to study the role of TIM-2 in immune responses. It helps researchers to understand how TIM-2 influences T cell activities and immune regulation.

3. Inhibition Assays: RMT2-14 can be used to block or inhibit TIM-2, thereby investigating its immunoregulatory functions in T cells during in vivo experiments.

4. Western Blot: It is also applied in Western blot analyses to detect TIM-2 protein levels in mouse tissues or cells.

While RMT2-14 is primarily associated with these applications, it is important to note that experiments involving TIM-2 often focus on its role in autoimmune diseases or immune regulation rather than direct therapeutic applications like cancer treatment.

Commonly Used Antibodies and Proteins with RMT2-14

RMT2-14 is a rat monoclonal antibody targeting mouse TIM-2 (T-cell immunoglobulin and mucin domain-containing protein 2), widely used in immunology research. In the literature, RMT2-14 is often used in combination with other antibodies and proteins for functional, comparative, or mechanistic studies, particularly in the context of immune cell biology.

Antibodies Frequently Co-Used with RMT2-14

• Anti-TIM-1 (RMT1-17) and Anti-TIM-3 (RMT3-23): These antibodies target other members of the TIM family (TIM-1 and TIM-3), often employed in comparative studies to investigate the roles and signaling differences among TIM family proteins.
• Anti-TIM-4 (RMT4-53): Used to study TIM-4, another member of the TIM family, enabling researchers to compare the effects and mechanisms of different TIM proteins in immune regulation.
• Anti-CD3 and Anti-CD28: These antibodies are commonly used to stimulate or activate T cells in culture, providing a functional context for assessing the impact of TIM-2 and its antibody modulators like RMT2-14 on T cell responses.
• Other anti-TIM-2 monoclonal antibodies (e.g., RMT2-26): Used for comparative binding and functional studies to validate the specificity and effects of RMT2-14.
• Isotype controls: Non-specific antibodies of the same isotype as RMT2-14 (rat IgG) are typically used as negative controls to confirm specific binding and biological effects.

Proteins and Ligands Commonly Studied with RMT2-14

• H-ferritin: RMT2-14 has been shown to inhibit the binding of H-ferritin to TIM-2, and studies often use H-ferritin as a ligand to investigate TIM-2 function and the blocking effect of RMT2-14.
• B cell activation markers: Given that RMT2-14 can enhance B cell proliferation and activation, markers of B cell activation (such as CD69, CD86, or proliferation dyes) are frequently measured alongside RMT2-14 treatment.
• Cytokines and chemokines: ELISA or flow cytometry assays for cytokines (e.g., IL-2, IFN-γ) or chemokines are often performed to assess downstream immune responses modulated by TIM-2 and RMT2-14.

Summary Table

Key Points

• RMT2-14 is most commonly used with other TIM family antibodies (TIM-1, TIM-3, TIM-4) for comparative studies.
• Anti-CD3 and anti-CD28 are standard tools for T cell activation assays and are often used in the same experimental systems as RMT2-14 to study TIM-2 function in T cell biology.
• H-ferritin is a key ligand for TIM-2, and RMT2-14’s ability to block this interaction is a major focus of mechanistic studies.
• B cell activation and proliferation markers are measured to assess the agonistic effects of RMT2-14 on B cells.
• Isotype controls are essential for confirming specificity in all such experiments.

These combinations reflect the standard toolkit for investigating TIM-2 biology and the functional consequences of modulating TIM-2 with RMT2-14 in immune cell assays.

The key findings from scientific literature on clone RMT2-14 focus on its role as a monoclonal antibody (mAb) that specifically recognizes mouse TIM-2 (T-cell immunoglobulin and mucin-domain containing molecule-2), an immune-regulatory molecule. Studies that cite or characterize RMT2-14 highlight several points:

• Specificity: RMT2-14 is one of three monoclonal antibodies (along with RMT2-25 and RMT2-26) developed to target mouse TIM-2. All these mAbs, including RMT2-14, react with cells expressing TIM-2 but not with negative controls, indicating high specificity for the antigen.

• Applications: These antibodies have been used to investigate TIM-2 expression and function in murine immune cells, supporting research into TIM-2's biological role in immunity and inflammation.

• Research Utility: RMT2-14 and related clones offer tools for both detection (such as flow cytometry or immunofluorescence) and functional studies exploring immune mechanisms involving TIM-2.

Additional related clones (notably RMT2-25) have been studied for blocking activity against TIM-2, demonstrating functional consequence on immune cell signaling, but direct literature about RMT2-14 specifically highlights its usefulness in identifying and studying TIM-2-expressing cells in mouse models.

There is currently no citation indicating therapeutic use or clinical findings for clone RMT2-14; its utility remains primarily in basic immunological research contexts.

Dosing regimens of clone RMT2-14 (an anti-mouse TIM-2 rat monoclonal antibody) vary according to the disease model and experimental objectives, but published sources primarily describe its use for immune regulation studies in mice, with dosing schedules tailored to specific models.

Essential context and supporting details:

• RMT2-14 is used to target mouse TIM-2 in immune-related disease models, such as autoimmune disorders and inflammation.
• Specific dosing regimens (amount, frequency, route) are not standardized in publicly available summaries; dosing is typically individualized based on model requirements and the desired extent of TIM-2 blockade or immune modulation.
• Most in vivo antibody studies utilize intraperitoneal injection, with doses for comparable antibodies (e.g., checkpoint inhibitors like anti-PD-1 and anti-CTLA-4) ranging between 100–500 μg per mouse administered every 3–4 days. This can be used as a general reference for in vivo monoclonal antibody treatment but should be validated for RMT2-14's specific pharmacodynamics and target engagement.
• No direct published data were found specifying exact RMT2-14 dosing regimens across multiple mouse models; researchers typically adjust antibody dose based on pilot toxicity studies, pharmacokinetics, or prior literature for analogous antibodies.
• Product information sheets for research-grade RMT2-14 recommend consulting the primary scientific literature or performing dose titration studies for optimal regimen selection.

Additional relevant information:

• Variation in dosing often reflects differences in disease severity, antibody half-life, and immune activation required for the studied condition.
• Tailored regimens may involve single or repeated dosing, with dose escalation approaches sometimes used to assess safety or efficacy, as is standard for novel in vivo antibody studies.
• If precise regimen details are required for your mouse models, it is best to consult primary research articles on RMT2-14 or related TIM-2 antibodies, if available, or engage in pilot studies to establish effective and safe dosing ranges.

In summary, while clone RMT2-14 is widely used in mouse immune regulation studies, exact dosing regimens are not universally established and are typically adjusted based on the disease model and experimental outcome measures, with reference to prevailing practices for similar antibodies.